



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

PTO/SB/06b (2-09)
Approved for use through 03/31/2009. GMB 0551-2031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

3

Application Number		10/627,358
Filing Date		July 23, 2003
First Named Inventor		Peter Migaly
Art Unit		Art Unit 1614
Examiner Name		Eric Olson
Attorney Docket Number		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/ESO/		Van Putten T. The many faces of akathisia Comprehensive psychiatry Vol 16 (1) 1975 43- 47.	
/ESO/		Zubenko G et al Antidepressant-related akathisia J Clin Psychopharmacol Vol 7(4) 1987 254-257.	
/ESO/		Lipinski J F. et al Fluoxetine-induced akathisia: Clinical and theoretical implications. J Clin Psychiatry 50:9 1989 pp 339-342.)	
/ESO/		Nair, NPV et al Neurochemical and receptor theories of depression. Psychiat J. Univ Ottawa, vol 14(2) 1989 pp 328- 341 p 328 first column lines 3-5 and 9-10.)	
/ESO/		Reeves H et al, Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry 69:8 2008 1228-1236. page 1229 first column 9-10	
/ESO/		Karoum F et al Marked reduction in indexes of dopamine metabolism among patients with depression who attempt suicide. Arch Gen Psychiatry 49, 1992 447-450. page 447 last two lines of first column and first two of second one, and p448 last four lines of second column.	
/ESO/		Hirsch SR et al The concept and efficacy of the treatment of parasuicide. Br J. clin Pharmac 1983, 15, 189S-194S table 1 on p. 189S.	
/ESO/		Poyurovsky M et al Mirtazapine for the neuroleptic-induced akathisia. Am J psychiatry 158:5 2001 p819 second paragraph first sentence.	
/ESO/		Hirose S et al. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J. Clin Psychiatry Vol 63, (8) August 2002, pages 733-736.	
/ESO/		Barbee J G et al's article Lamotrigine as an augmentation agent in treatment-resistant depression. J.Clin Psychiatry 63:8 August 2002 p 737-741.	

Examiner Signature	/Eric Olson/	Date Considered	08/26/2009
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-787-9199) and select option 2.

PTO/SB/08b (02-09)

Approved for use through 03/31/2009 OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known
		Application Number	10/627,358	
		Filing Date	July 23, 2003	
		First Named Inventor	Peter Migaly	
		Art Unit	Art Unit 1614	
		Examiner Name	Eric Olson	
Sheet	2	of	3	Attorney Docket Number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/ESO/		Evins et al. Am. J. Psychiatry 156:5, May 1999 pages 798-799.	
/ESO/		Battaglia J et al Structured assessment and depot fluphenazine treatment of multiple suicide attempts in the emergency department. International Clinical Psychopharmacology 1999, 14: 361-372.	
/ESO/		Steiner M. The neurochemistry of mood. Psychiat J. Univ Ottawa, vol 14(2) 1989 pp342-343. p 342 first column lines 5-8;	
/ESO/		Montgomery SA et al Br J. clin Pharmac 1983, 15, 183S-188S, p 183S second column second paragraph, and p185S first column third paragraph	
/ESO/		Hirsch SR et al The concept and efficacy of the treatment of parasuicide. Br J. clin Pharmac 1983, 15, 189S-194S table 1 on p. 189S.	
/ESO/		Van Putten T et al Behavioral toxicity of antipsychotic drugs, J Clin Psychiatry 48 [9, Suppl]:13-19, 1987,	
/ESO/		Drake RE et al Suicide attempts associated with akathisia Am J Psychiatry 142:4, April 1985;	
/ESO/		Shear, M. K. et al Suicide associated with akathisia and depot fluphenazine treatment. Journal of Clinical Psychopharmacology Vol. 3 (4) 1983 235-236.	
/ESO/		Blum A Patients at risk of developing severe side effects from depot fluphenazine treatment Am J Psychiatry 137:2 1980 254-255.	
/ESO/		Shaw ED et al A case of suicidal and homicidal ideation and akathisia in a double-blind neuroleptic crossover study J clin psychopharmacol Vol 6(3) 1986 196-197.	

Examiner Signature	/Eric Olson/	Date Considered	08/26/2009
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to require 0 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08b (02-09)

Approved for use through 03/31/2009. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

*Complete If Known***INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Application Number	10/627,358
Filing Date	July 23, 2003
First Named Inventor	Peter Migaly
Art Unit	Art Unit 1614
Examiner Name	Eric Olson

Sheet

3

of

3

Attorney Docket Number

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/ESO/		Smith WT et al. Short term augmentation of fluoxetine with clonazepam in the treatment of depression: A double-blind study. Am J Psychiatry 155:10 1998 1339-45.	
/ESO/		Tsai G E. A new class of antipsychotic drugs Enhancing neurotransmission by NMDA receptors Psychiatric Times December 2008, p 16-18.	
/ESO/		Viner MW et al Low-dose risperidone augmentation of antidepressants in nonpsychotic depressive disorders with suicidal ideation. Journal of Clinical Psychopharmacology 23:1 2003.	
/ESO/		Reeves H et al Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled study. J. Clin Psychiatry 69:8 August 2008)	

Examiner Signature	/Eric Olson/	Date Considered	08/26/2009
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Receipt date: 03/18/2009

10627358 - GAU: 1623



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08a (02-09)

Approved for use through 03/31/2009, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Use as many sheets as necessary.

Sheo

10

Complete if Known

Application Number	10/627,358
Filing Date	July 23, 2003
First Named Inventor	Peter Migaly
Art Unit	Art Unit 1614
Examiner Name	Eric Olson
Attorney Docket Number	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ^a Number ^b Kind Code ^c (if known)			T#
/ESO/		EP 0966967 A2		Tollefson and Eli Lilly	
/ESO/		EP 0958824 A2		Tollefson and Eli Lilly	
/ESO/		WO 02/053140 A2		Nesbitt and Pharmacia & Upjohn	
/ESO/		EP 1 23 867 6 A1		Ralph - Pfizer	

Examiner Signature	/Eric Olson/	Date Considered	08/26/2009
-----------------------	--------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not otherwise considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.